TY - JOUR
T1 - Adjuvant antiestrogen therapy for breast cancer
T2 - Past, present, and future
AU - Gibson, D. F.C.
AU - Jordan, V. C.
PY - 1990
Y1 - 1990
N2 - Laboratory investigations using animal models of breast cancer growth have indicated that the antiestrogenic compound tamoxifen is a tumoristatic agent. It is therefore effective in suppressing, rather than destroying, the breast tumor. Its use as an adjuvant in breast cancer management has been successful, with a proportion of women benefiting from long periods of tamoxifen treatment. All the initial studies recruited postmenopausal women, but tamoxifen is now proposed for the treatment of premenopausal women for an extended time. Naturally, there are many aspects of the toxicology of tamoxifen to consider; however, careful monitoring of clinical trials will determine the safety of the drug for the general patient population.
AB - Laboratory investigations using animal models of breast cancer growth have indicated that the antiestrogenic compound tamoxifen is a tumoristatic agent. It is therefore effective in suppressing, rather than destroying, the breast tumor. Its use as an adjuvant in breast cancer management has been successful, with a proportion of women benefiting from long periods of tamoxifen treatment. All the initial studies recruited postmenopausal women, but tamoxifen is now proposed for the treatment of premenopausal women for an extended time. Naturally, there are many aspects of the toxicology of tamoxifen to consider; however, careful monitoring of clinical trials will determine the safety of the drug for the general patient population.
UR - http://www.scopus.com/inward/record.url?scp=0025175059&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025175059&partnerID=8YFLogxK
U2 - 10.1016/S0039-6109(16)45232-1
DO - 10.1016/S0039-6109(16)45232-1
M3 - Article
C2 - 2218821
AN - SCOPUS:0025175059
SN - 0039-6109
VL - 70
SP - 1103
EP - 1113
JO - Surgical Clinics of North America
JF - Surgical Clinics of North America
IS - 5
ER -